Observing Intravenous Lacosamide as a Rescue Treatment for Acute Pain in Adults with Trigeminal Neuralgia

What this Trial Is About

Researchers are evaluating the use of intravenous lacosamide as a rescue treatment for sudden worsening of pain in patients with trigeminal neuralgia, a condition marked by severe facial pain that can be difficult to manage with standard treatments. This prospective observational study aims to assess the effectiveness and safety of lacosamide when given in an emergency department setting. The trial is sponsored by Hospital Universitari de Bellvitge and involves about 20 patients over two years. During the study, patients presenting with acute trigeminal neuralgia pain will receive intravenous lacosamide based on their doctors decision. The medication will be given following standard clinical practice, with continuous monitoring of heart function during and after the infusion. Patients will stay in the emergency department for at least two hours after treatment, with follow-up calls scheduled at 24 hours and seven days to check on their condition. Participants will be assessed using several measures including an 11-point pain rating scale at different times after treatment, changes in attack frequency, impact on daily activities, patient satisfaction, duration of pain relief, and any side effects. Data collection will include patient demographics, pain characteristics, prior treatments, and medication details. The study will provide real-world information on lacosamides role in managing acute pain episodes in trigeminal neuralgia and may help guide future research and treatment recommendations.

Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia